SCHEMBL2783095

SCHEMBL2783095

COCCN1CCN(c2cccc(F)c2C(F)(F)F)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
MAPK1 P28482 1/20 0.45
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 2/20 0.43
TSHR P16473 2/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.42
HTR1A P08908 2/20 0.42
RBP4 P02753 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
GNRHR P30968 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
DRD2 P14416 3/20 0.41
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
LMNA P02545 2/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A3 Q01959 2/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2783879 0.86 DRD2 (0.50) KDM4EHTR1ADRD2HTR2ALMNA
SCHEMBL2781887 0.85 DRD2 (0.54) SMN1; SMN2MAPK1ALDH1A1KDM4ETSHR
SCHEMBL2783063 0.83 DRD2 (0.54) SMN1; SMN2MAPK1ALDH1A1KDM4ETSHR
SCHEMBL2783046 0.82 SMN1; SMN2 (0.48) SMN1; SMN2MAPK1ALDH1A1KDM4ETSHR
SCHEMBL2802128 0.82 KDM4E (0.48) SMN1; SMN2MAPK1ALDH1A1KDM4ETSHR
SCHEMBL2783220 0.82 DRD2 (0.45) SMN1; SMN2ALDH1A1HTR1AHTR1DHTR1B
SCHEMBL2782579 0.81 DRD2 (0.53) SMN1; SMN2MAPK1ALDH1A1KDM4ETSHR
SCHEMBL2781296 0.81 ALDH1A1 (0.49) SMN1; SMN2MAPK1ALDH1A1KDM4ETSHR
SCHEMBL2803040 0.81 SMN1; SMN2 (0.47) SMN1; SMN2MAPK1ALDH1A1KDM4ETSHR
SCHEMBL2785397 0.79 ALDH1A1 (0.44) ALDH1A1KMT2AHTR1AHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2010-10-07 US claimed
EP-2204363-A1 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2010-07-07 EP claimed
CN-1997630-A New disubstituted phenylpiperidines as modulators of dopamine neurotransmission NEUROSEARCH SWEDEN AB (SE) 2007-07-11 CN claimed
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2007-06-28 US claimed
CN-1997630-B New disubstituted phenylpiperidines as modulators of dopamine neurotransmission NEUROSEARCH SWEDEN AB 2013-01-30 CN disclosed
US-8314126-B2 Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2012-11-20 US disclosed
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2010-10-07 US disclosed
US-7763639-B2 Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2010-07-27 US disclosed
EP-2204363-A1 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2010-07-07 EP disclosed
CN-1997630-A New disubstituted phenylpiperidines as modulators of dopamine neurotransmission NEUROSEARCH SWEDEN AB (SE) 2007-07-11 CN disclosed
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, DRD4, DRD1 SMN1; SMN2 1353/4885MAPK1 639/4885ALDH1A1 1194/4885
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, DRD4, DRD1 SMN1; SMN2 1180/4885MAPK1 597/4885ALDH1A1 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.